A new treatment for multiple food allergies using a small molecule compound.
Official title: IgE-suppressing small molecule compound Xanthopurpurin analog for multiple food allergies
Funded at General Nutraceutical Technology, LLC · NIH-10761370 · Data updated 2026-11-12
This study is testing a new daily pill called xanthopurpurin that could help lower allergy levels in people with multiple food allergies, making it easier and safer for them to manage their condition without having to avoid certain foods.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | General Nutraceutical Technology, LLC NIH-funded |
| Lab location | 1 site (Briarcliff Manor, UNITED STATES) |
| Project start | July 12, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $289,622 |
| NIH project number | 1R41AI172572-01A1 |
| Project ID | NIH-10761370 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with multiple food allergies, particularly those with peanut and tree nut allergies.
✕Less likely to help
Patients with single food allergies or those who do not have elevated IgE levels may not benefit from this research.
What this research studies
This research investigates a small molecule compound called xanthopurpurin, which has the potential to suppress IgE levels in patients with multiple food allergies. The study aims to develop a non-food restricted treatment that can effectively reduce elevated food-specific immunoglobulin E (sIgE), which is a major contributor to food allergy reactions. By utilizing a once-a-day oral dosage of this compound, the research seeks to provide a safer and more effective management option for individuals suffering from severe food allergies, including peanut and tree nut allergies. The approach is based on preliminary findings that suggest the compound is stable and has a favorable safety profile.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that significantly improves the quality of life for patients with multiple food allergies.
How similar studies have gone: While the approach of using small molecule compounds for food allergies is relatively novel, preliminary data from similar research has shown promise in reducing IgE levels.
Where this research is happening
-
General Nutraceutical Technology, LLC
Briarcliff Manor, United States Active
Researchers
- Principal investigator: Li, Xiu-Min — General Nutraceutical Technology, LLC
- Study coordinator: Li, Xiu-Min
Related research
Other NIH-funded projects on the same topics.
-
Using berberine nanomedicine to reduce food allergies
This study is testing a new pill made with a special ingredient called berberine to help people with food allergies, especially those allergic to peanuts and tree nuts, by making their immune system less reactive to these foods.
-
Using berberine to reduce allergic reactions to peanuts and tree nuts
This study is looking at whether taking berberine, a natural supplement, can help reduce the allergy-triggering antibodies in people with peanut and tree nut allergies, with the hope of making life safer and easier for those affected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.